JZP815

JZP815 is an orally available, small molecule pan-RAF kinase inhibitor developed to target all members of the serine/threonine protein kinase RAF family, including A-Raf, B-Raf, and C-Raf. It is designed to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs by inhibiting the entire RAF family and thereby blocking aberrant signaling through the RAS-RAF-MAPK pathway—a pathway frequently mutated in a wide range of cancers. Preclinical studies have shown efficacy in models of both B-RAFV600E mutant and RAS-mutant colorectal cancer where existing B-RAF inhibitors are ineffective. The drug was originally discovered by Redx Pharma and later acquired by Jazz Pharmaceuticals, which is currently developing it for use in advanced or metastatic solid tumors[1][5][6][7].